The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

FDA grants priority review for Eli Lilly's olaratumab to treat soft tissue sarcoma.....           Ergomed to acquire Haemostatix.....           Bayer's Stivarga increases overall survival in liver cancer patients.....           Concert Pharmaceuticals unveils CTP-543 to treat alopecia areata.....           Merck to expand Carlsbad viral and gene therapy plant in California.....           Sirnaomics raises $10m to fund clinical development of anti-fibrosis programs.....           Helsinn unveils top-line results of phase IIb trial with elsiglutide to prevent chemotherapy-induced diarrhea in colorectal cancer patients.....           Biogen looks to spin off hemophilia business to focus on neurology medicines.....           Foamix announces completion of enrollment in phase II clinical trial of minocycline foam to treat papulopustular rosacea.....           TG Therapeutics launches first clinical trial in multiple sclerosis for TG-1101.....           Ionis Pharmaceuticals and Kastle Therapeutics announce acquisition of Kynamro.....           Celtaxsys begins EU enrollment for CF lung function preservation trial of Acebilustat anti-inflammatory therapy for cystic fibrosis.....           Johnson & Johnson to appeal $55m compensation awarded in talcum powder case.....           Protalex receives positive interim review in European phase 1b study of PRTX-100 to treat immune thrombocytopenia.....           Veristat acquires UK-based CRO, Spero Oncology.....           Kastle Therapeutics to acquire rights of Kynamro from Ionis Pharmaceuticals.....           FDA approves new formulation of Eisai?s Fycompa to treat seizure disorders.....           Researchers find new treatment for lethal resistant prostate cancers.....           Graybug Vision secures $44.5m funding for clinical development activities.....           Health Canada approves Vanc Pharmaceuticals' Cortivera-H product for minor skin irritations.....           Perrigo receives final FDA approval for generic version of Valeant's BenzaClin Pump Topical Gel.....           Seres achieves target enrollment of SER-109 phase 2 study to prevent recurrent clostridium difficile infection.....           EMD Serono expands biopharmaceutical R&D facility in Billerica, Massachusetts.....           Business Review is looking for a new online reporter.....           FDA approves Acadia's Nuplazid to treat Parkinson?s disease psychosis.....           European CHMP adopts positive opinion for Afinitor to treat select GI and lung neuroendocrine tumors.....           Gilead Sciences receives positive CHMP opinion for Odefsey to treat HIV.....           Heritage Pharmaceuticals issues product safety warning counterfeit drug product BiCNU.....           Concert Pharmaceuticals unveils positive data from multiple dose phase 1 trial of CTP-656.....           Ablynx announces milestone in drug discovery collaboration with Novartis.....           BioQ Pharma expands US license and supply deal with Sandoz.....           Sanofi offers to buy Medivation for $9.3bn.....           Neovacs wins FDA approval to extend phase IIb clinical trial in Lupus to US.....           AbbVie agrees to buy Stemcentrx for $5.8bn.....           Therabron Therapeutics wins FDA fast track designation for rhCC10.....           Alnylam breaks ground on new manufacturing Facility in Norton, Massachusetts.....           Alkermes plans to start second clinical trial of ALKS 7119.....           Theratechnologies unveils completion of enrollment for phase III Ibalizumab trial.....           Novartis' Ilaris wins three FDA breakthrough designations to treat periodic fever syndromes.....           Celldex starts phase 1/2 study of glembatumumab vedotin in squamous cell lung cancer.....           Ocular completes end-of-phase 2 review with FDA for OTX-TP for glaucoma and ocular hypertension.....           IBC Generium selects Goodwin Biotechnology to optimize process of IgG-based bispecific antibody.....           X-Chem achieves milestone in drug discovery collaboration with Alexion Pharmaceuticals.....           Cumberland Pharmaceuticals unveils new program to develop Vasculan for systemic sclerosis.....           European Commission grants marketing authorisation to Lonsurf in mCRC.....           AstraZeneca sells US rights to gout drug Zurampic to Ironwood Pharmaceuticals.....           NewLink Genetics wins $21.6m contract option from BARDA for Ebola vaccine development.....           FDA committee votes against approval of Sarepta's duchenne muscular dystrophy drug.....           Pfizer completes patient enrollment in bococizumab SPIRE-2 cardiovascular outcome trial.....           Collegium Pharmaceutical's Xtampza ER opioid painkiller wins FDA approval.....           Arch Biopartners' AB569 receives positive opinion from EMA COMP.....           Zymeworks, GSK enter second collaboration to develop bi-specific antibodies.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.
Recent meetings

APS PharmaFocus Day at Pfizer
24 February 2016 - Sandwich

The first of three proposed APS PharmaFocus Days took place in February. This event was hosted by Pfizer at their Sandwich facilities. Further PharmaFocus Days will take place later in the year at AstraZeneca (June) and Bristol-Myers Squibb (November).

These events are an opportunity for undergraduate and postgraduate pharmaceutical science students considering a career in the pharmaceutical industry to have some first-hand experience.

Click here... to read a report of the Pfizer event.

Please also see details of our forthcoming Industrial Insights event to be held at GSK in Ware on 11 & 12 April 2016. This is a two day event and is also aimed at undergraduate and postgraduate students interested in exploring opportunities in the Pharmaceutical Industry.

APS 20th Anniversary International Pharmaceutical Photostability Conference 2015
5-7 October 2015 - Loughborough

In this International Year of Light 2015, the APS was particularly pleased to present this event, which was a one-day workshop and a two-day conference.
The course was suitable for those who are new to the topic of pharmaceutical photostability and photostability testing and also for those who wished to brush up on the basic concepts prior to the PPS’015 conference that followed it.


Latest News
APS Alternatives to Antibiotics Meeting
APS Alternatives to Antibiotics Meeting Thursday 16th June 2016 Burleigh Court - Loughborough. Keynote speaker- Dr Lloyd Czeplewski, Chairman of the Wellcome Trust/Department of Health funded review on Alternative to Antibiotics. This one day meeting focussing on exploration of possible opportunities for alternative approaches to traditional antibacterial compounds as potential clinical approaches for treating infectious diseases will be held on Thursday 16th June 2016 at Burleigh Court, Loughborough, Leicestershire ( organised by the APS Microbiology and Anti-infectives Focus Group.. Background to the Meeting:. The withdrawal last Century by the majority of Big Pharma from antibiotic research and development programmes, coupled with other aspects such as a lack of global stewardship over use, has led to the current situation where resistance has left a critical lack of efficacious compounds. The pipeline for development of new antimicrobial agents is critically stagnant and the time to seriously examine viable alternatives for tackling multi-drug resistant pathogens has arrived. The purpose for this meeting will be to allow delegates to hear presentations on a series of alternative approaches including bacteriophage and endolysin therapy, probiotics, antibody technology and immune intervention, which collectively represent the most likely of the alternative approaches to yield genuine clinical impact. Our speakers will highlight the current knowledge base of development in the field in pursuit of discovery of alternatives to antibiotics.. The purpose and aims of the APSGB Microbiology and Anti-Infectives Focus Group is to provide a forum for the discussion of all aspects of microbiology and anti-infectives research and development in the pharmaceutical industry and academia, to underpin the importance of microbiology to the pharmaceutical sciences and innovation, and to provide continuing education, resources and a voice for pharmaceutical scientists in the challenging area of antimicrobials development.. Meeting Format: . We are very pleased to offer a stimulating one day programme of presentations from high profile speakers who are leading experts in their particular fields of research into alternative approaches to traditional small molecule antibiotics, and include representatives of academia, biotechnology SMEs and the pharmaceutical industry.. The Keynote lecture will be delivered by Dr Lloyd Czeplewski, Chairman of the Wellcome Trust/Department of Health funded review on Alternative to Antibiotics, which was published in Lancet Infectious Diseases in January 2016 ( Dr Czeplewski is Founder and Director of Chemical Biology Ventures in and Abgentis, is an international opinion leader and successful scientist entrepreneur in the antibacterial R&D sector. He is currently a champion of the Alternatives to Antibiotics pioneering approaches for treatment of infectious diseases and he will be speaking specifically on this topic.. For more information and registrations, please visit us online at:.
Pharmaceutical Sciences: Improving World Health 7th APS International PharmSci Conference . Monday 5th – Wednesday 7th September 2016 at the Technology and Innovation Centre, University of Strathclyde, Glasgow. How will you benefit from attending this year’s APS International Pharm Sci Conference?. ‘The conference put the icing on the cake. The APS can provide you with these opportunities to make those valuable connections and help you decide if industry is right for you. It’s really helped kick start my career, I can’t urge you enough to get involved and join today!’. Robert Oakley-University of Nottingham – Quote from a Student who attended last year’s conference. Register now to benefit from discounted rates of £66 for one day and up to £170 for three days for at the early bird rate until 31st July 2015. Additional discounts are available for APS members.. What Pharm Sci offers you?. · Opportunity to present your research work via a poster or being selected for a podium presentation. · Network with a broad range of scientists from fellow students to eminent professors from the key UK Universities. · Learn about the latest innovative science by attending a variety of sessions demonstrating how Pharmaceutical Scientists are striving to improve patient health globally · Understand how Pharmaceutical Science is applied in the Industry and what opportunities this might present for you by engaging with representatives from the Pharmaceutical Industry including Pfizer, Astra Zeneca, GSK and BMS.. . Pharm Sci includes:. · A session by the Student Association of the APS (SAPS) on Increasing your employability after your degree. · A session by the APS New Scientist Focus Group offering the opportunity for new scientists to present on Novel Approaches for Improving Health. · View and discuss posters and hear selected abstracts presented at the podium. · Visit the conference exhibition to see and talk to a range of companies offering the latest pharmaceutical science technologies and learn about potential career opportunities.. Book now at to be part of this leading Pharmaceutical Sciences Conference and gain an insight into the opportunities within the Pharmaceutical Sciences..
APS Conference Report:-Emerging nanomedicine applications and manufacturing: progress and challenges
6th APS International PharmSci Conference 7–9 September 2015 East Midlands Conference Centre, University of Nottingham, Nottingham, UK.. The APS is pleased to announce that, a conference report written jointly by members of the APS Nanomedicines focus group and the British Society for Nanomedicine (BSNM) has been published.. The Academy of Pharmaceutical Sciences (APS) and the British Society for Nanomedicine (BSNM) organized a one-day session as part of the annual APS PharmSci conference, to discuss some of the latest developments in nanomedicine particularly in the areas of cancer, infection and targeting of the CNS. The meeting report can be accessed via the following link:. For details of this year’s PharmSci conference please visit.
APS PharmSci 2016 Announcement Christine Allen and Gavin Halbert
Announcement of Guest Plenary Speakers at The International APS PharmSci Conference 2016.. 'Pharmaceutical Sciences: Improving World Health' Monday 5th – Wednesday 7th September 2016 Technology and Innovation Centre, University of Strathclyde, Glasgow. The APS are pleased to announce that Christine Allen who is a Professor and the GlaxoSmithKline Chair in Pharmaceutics and Drug Delivery in the Leslie Dan Faculty of Pharmacy at the University of Toronto will be delivering a plenary lecture on Tuesday 6th September 2016.. Her talk is entitled ‘The Promise of Nanotechnology in Oncology: The Time is Now’.. This is an exciting time for nanotechnology in oncology with a number of new nanomedicines and nano-based imaging agents in clinical development, announcements of positive clinical data and pharmaceutical deals totaling billions of dollars. This lecture will take account of the current status and identify the challenges that must still be overcome in order to further exploit the power of nanotechnology in oncology. Special attention will be given tothe integration of imaging to fast-track pre-clinical development of nanomedicines and to personalize clinical development as a means to better assure improved outcomes.. Christine completed her doctoral research in the Department of Chemistry at McGill University and post-doctoral research in the Department of Advanced Therapeutics at the B.C. Cancer Agency. She joined The University of Toronto in 2002, from Celator Pharmaceuticals Inc. where she had worked as a scientist and Assistant Director of materials research. She has over 100 peer-reviewed publications, numerous patent applications, and nine book chapters on both lipid and polymer-based delivery systems. She has served on several peer review panels for granting agencies including CIHR (2004, 2005-2009, 2011), NCIC (2005,2006) and NIH (2006, 2008, 2011 - 2016). She was awarded a CIHR-Rx&D Career Award (2004-2009) for her research on the design and development of technologies for cancer treatment. She has also received the Association of Faculties of Pharmacy of Canada/AstraZeneca New Investigator Research Award, the Canadian Society Pharmaceutical Science/GlaxoSmithKline Early Career Award, an Innovation Award from. the Ontario Research Commercialization Program and the Jorge Heller Controlled Release Society (CRS) Best Paper Award. She is an Associate Editor for the ACS journal Molecular Pharmaceutics and is actively involved in numerous scientific societies including as Treasurer Elect and Deputy Chair of the Program Committee for the Controlled Release Society.. . The APS is also pleased to announce that Prof Gavin Halbert who is a Director, Cancer Research UK Formulation Unit, Strathclyde Institute of Pharmacy and Biomedical Sciences, will be delivering a plenary lecture on Wednesday 7th September 2016.. His talk is entitled The Impact of Cancer Chemotherapy on Formulation, Manufacture and Supply.. Over the past two decades cancer chemotherapy has been revolutionised by developments in molecular biology which have permitted the targeting of specific molecular defects. The physicochemical properties of anti-cancer drugs have therefore dramatically changed and this has impacted on the formulations required to deliver effective therapy. In addition targeted therapy is presenting future challenges related to the supply and distribution of products to specific patient groups. These developments will be explored through the role of the Cancer Research UK Formulation Unit.. Prof Halbert is a pharmacist and chemist (University of Strathclyde 1979) with a PhD in Physiochemical Aspects of Anti-Cancer Drug Targeting Systems (University of Strathclyde 1984). He was appointed as a lecturer in pharmaceutical sciences at University of Strathclyde in 1984 and Director of the Cancer Research UK Formulation Unit in 1992. The Unit's role is to characterise, analyse, formulate and manufacture putative anti-cancer drugs accepted by Cancer Research UK’s New Agents Committee for use in human clinical trials. Personal experience of pharmaceutically progressing over 30 novel NCEs into clinical trials, including agents such as temozolomide and abiraterone acetate. Research interests include medicinal and analytical chemistry, drug physiochemistry, formulation for both parenteral and oral products and the GMP production of specialist pharmaceutical products for phase l clinical trials. The latter incorporates research areas such as microbiology and lyophilisation. Related research is also conducted in drug targeting and delivery systems for cancer chemotherapy for example the utilisation of synthetic Low Density Lipoprotein systems and the biopharmaceutical assessment of new formulations. . For more information on the conference, and to submit an abstract please visit the Conference Website regularly to keep updated on further announcements.. Register at on or before 31st July 2016 to take advantage of the Early Bird Rates for the conference.. .
Follow us
Upcoming Events
APS Excipients - selection, control, application and suitability
23 - 24 May 2016
APS PharmaFocus Day
June 2016
APS Alternatives to Antibiotics
16 June 2016
CGOM 12 (12th International Workshop of the Crystal Growth of Organic Materials)
26 - 30 June 2016
Symposium of Digital Design of Drug Products - Joint meeting with the British Association of Crystal Growth
1 July 2016
Job Vacancies
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.